

This article was downloaded by:

On: 25 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Oligonucleotide Charge Reversal: 2'-O-Lysylaminohexyl Modified Oligonucleotides

Johannes Winkler^a; Christian R. Noe^a

^a Department of Medicinal Chemistry, University of Vienna, Vienna, Austria

To cite this Article Winkler, Johannes and Noe, Christian R.(2007) 'Oligonucleotide Charge Reversal: 2'-O-Lysylaminohexyl Modified Oligonucleotides', *Nucleosides, Nucleotides and Nucleic Acids*, 26: 8, 939 — 942

To link to this Article: DOI: 10.1080/15257770701507978

URL: <http://dx.doi.org/10.1080/15257770701507978>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

OLIGONUCLEOTIDE CHARGE REVERSAL: 2'-O-LYSYLAMINOHEXYL MODIFIED OLIGONUCLEOTIDES

Johannes Winkler and Christian R. Noe □ *Department of Medicinal Chemistry, University of Vienna, Vienna, Austria*

□ *A novel cationic building nucleoside building block designed for antisense and siRNA oligonucleotides is presented. Protected L-lysine was coupled to 2'-O-aminohexyluridine and the resulting nucleoside was phosphitylated for automated oligonucleotide synthesis. An increasing number of these 2'-O-lysylaminoheptyl nucleosides lowered the melting temperature of deoxy-thymidine homododecamers, but the decrease was lower than that for DNA/RNA hybrids. Incubation with an exonuclease showed the exceptionally high resistance against enzymatic degradation. CD spectrometry revealed a gradual transition towards an A-type oligonucleotide structure. Based on these data, the cationic building block is particularly suited for gapmer antisense as well as siRNA oligonucleotides.*

Keywords Antisense oligonucleotides; siRNA; cellular uptake; CD spectrometry

Gene silencing mediated by antisense oligonucleotides (ASO) or short interfering RNA (siRNA) has become an important technique in scientific research in the last decade. Attempts to exploit it for therapeutic purposes have so far been hampered by poor pharmacokinetic and pharmacodynamic properties as well as off-target effects caused by the chemical structures of oligonucleotides used in clinical trials.

In particular, the polyanionic nature of oligonucleotides all but prevents their uptake into living cells. Charge reduction or neutralization by zwitterionic nucleotide building blocks can give positive effects not only on cellular uptake, but also on target affinity.^[1,2] Conjugating cationic peptides to oligonucleotides has been shown to improve cellular uptake.^[3,4] We present a cationic building block that results in a charge reversal, as its incorporation in an oligonucleotide adds a positive charge instead of the negative one of a wild-type nucleoside.

The synthesis of the cationic uridine building block **5** proceeds in two steps from protected 2'-O-aminohexyl uridine^[1] (Figure 1). A trifluoro

Address correspondence to Johannes Winkler, Department of Medicinal Chemistry, University of Vienna, Centre of Pharmacy, Room 2E 362, Althanstrasse 14, A-1090 Wien, Austria. E-mail: johannes.winkler@univie.ac.at




FIGURE 1 Synthesis scheme of 2'-O-lysaminohexyl building block 5.

acetate protected L-lysine building block, prepared from L-lysine using trifluoroacetate, is coupled to the free amino group in excellent yield using DIC as catalyst. After phosphitylation, the building block can be used in standard oligonucleotide synthesis when extended coupling times are employed.


For an evaluation of the biophysical parameters of charge reversed oligonucleotides, desoxy-thymidine homododecamers incorporating an increasing number of building block 5 were used. The decrease in target affinity as determined by transition temperatures (T_m) and free energy values (ΔG) was lower than expected for dT-rU hybrids, indicating an increase in target affinity caused by the cationic lysine chains (Table 1). The calculated values were determined by a nearest neighbor model and take into account the poorer hybridization affinity of rU compared to dT. Data show that a few terminal cationic nucleotides are tolerated very well, whereas a pronounced influence on duplex stability was observed with several modifications spread over the entire oligonucleotide strand.

TABLE 1 Sequences and properties of oligonucleotides **7–13**. U*: 2'-*O*-Lysylaminohexyl-uridine

Sequence	T _m meas.	T _m calc.	ΔΔG meas.	ΔΔG calc.	MW calc.	MW found
5'-TTT TTT TTT TTT-3'	34,7	31,0	0,0	0,0	3577,4	3576,3
7 5'-U*TT TTT TTT TTT-3'	33,6	25,1	0,0	1,7	3817,7	3816,0
8 5'-U*U*T TTT TTT TTT-3'	32,4	22,7	0,0	5,0	4047,0	4048,0
9 5'-U*U*U* TTT TTT TTT-3'	30,4	20,6	1,4	8,4	4276,3	4276,0
10 5'-U*U*U* U*TT TTT TTT-3'	28,3	18,6	3,8	11,8	4505,6	4505,6
11 5'-U*U*U* U*U*T TTT TTT-3'	26,2	16,8	3,9	15,1	4735,0	4734,7
12 5'-TTU* TTT U*TT TU*T-3'	17,6	19,6			4276,3	4282,0
13 5'-TU*T TU*T TU*T TU*T-3'	9,5	17,7			4505,6	4507,0

MALDI analyses confirmed the successful incorporation of lysine amino-hexyl uridine into oligonucleotides. Neither transacetylation of lysine amino groups during synthesis nor cleavage of the amide bond during standard ammonia deprotection occurred.

Incubation of **7** with 5'-exonuclease revealed the excellent stability of charge reversed oligonucleotides (Figure 2). Only one modified nucleotide leads to practically complete resistance against enzymatic degradation. Lysylaminohexyl oligonucleotides are clearly superior to amino-hexyl

**FIGURE 2** HPLC of **7** (top) and T₁₂ (bottom) after 30 minutes of incubation with phosphodiesterase.




FIGURE 3 CD spectra of duplexes of 7–13 with dA₁₂.

modified ones, where three terminal modifications are required for a similar effect.^[1]

CD spectra of duplexes with wild-type DNA sense showed a conversion towards an A-type oligonucleotide secondary structure with increasing number of modified building blocks (Figure 3). The characteristic double peak of dA₁₂-dT₁₂ gradually disappears. In addition, the oligonucleotides with the highest number of cationic nucleotides exhibit a strong negative band in the far UV region, a characteristic of an A-type structure, often associated with RNA.

In conclusion, 2'-O-lysylaminohexyl modified oligonucleotides exhibit auspicious biophysical characteristics. In particular, the gapmer approach promises a positive effect on target affinity and sufficient stability against degrading enzymes at the same time.

REFERENCES

1. Noe, C.R.; Winkler, J.; Urban, E.; Gilbert, M.; Haberhauer, G.; Brunar, H. Zwitterionic oligonucleotides: A study on binding properties of 2'-O-aminoethyl modifications. *Nucleot. Nucleot. Nucl.* **2005**, *24*, 1167–1185.
2. Winkler, J.; Urban, E.; Noe, C.R. Oligonucleotides conjugated to short lysine chains. *Bioconjug. Chem.* **2005**, *16*, 1038–1044.
3. Fraley, A.W.; Pons, B.; Dalkara, D.; Nullans, G.; Behr, J.P.; Zuber, G. Cationic oligonucleotide-peptide conjugates with aggregating properties enter efficiently into cells while maintaining hybridization properties and enzymatic recognition. *J. Am. Chem. Soc.* **2006**, *128*, 10763–10771.
4. Sazani, P.; Kang, S.H.; Maier, M.A.; Wei, C.; Dillman, J.; Summerton, J.; Manoharan, M.; Kole, R. Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs. *Nucleic Acids Res.* **2001**, *29*, 3965–3974.